Joint Hypertension 2018 Scientific Sessions

AHA Council on Hypertension | AHA Council on Kidney in Cardiovascular Disease
American Society of Hypertension

September 6–9, 2018
Hyatt Regency Chicago | Chicago, Ill.
Registration Information
Take advantage of Early Registration prices through July 6, 2018.

See more Registration and Housing information.
Abstract Submission
NEW Late-Breaking Abstracts are now closed.


You can also click on each day below for a daily breakout:

Click on a day/date to expand or collapse

#Hypertension18 Thursday, Sept. 6
7:00 – 7:45 a.m.Coffee & Exhbits
7:45 – 8:00 a.m.President's Welcome
Ivor Benjamin, MD, FAHA, AHA President
Karen Griffin, MD, FAHA, Chair, Fall Conference Planning Committee
Joey Granger, PhD, FAHA, Chair, Council on Hypertension
8:00 – 10:00 a.m.Session 1 -  Recent Advances in Hypertension
Highlights of the New Hypertension Guidelines – Jan Basile, MD, FAHA
Implementation of the New Hypertension Guidelines – Brent Egan, MD, FAHA
Clinical Hypertension Research: Where Do We Go From Here? – Suzanne Oparil, MD, FAHA
Recent Advances and Future Directions in Basic Research – David Ellison, MD, FAHA
10:00 – 10:30 a.m.Refreshment Break
10:30 – 11:10 a.m.Session 2 - Recent Advances: Lifestyle Modifications and Impact on BP
Optimizing Cardiometabolic Health – Robert J. Chilton, DO, FACC, FAHA
The Anti-Aging Effects of Aerobic Exercise on Systemic Arteries – Hirofumi Tanaka, PhD
11:10 – 12:00 p.m.Session 3 - Recent Advances: Obesity and Cardiovascular Disease
Obesity Paradox in Hypertension: Should the SNS Be a Target to Improve Cardiometabolic Risk? – Elisabeth Lambert. PhD, Swineburne University of Technology
Cardiovascular Disease and Obesity: Recent Advances and Future Directions – John Hall, PhD, FAHA
12:00 – 1:30 p.m.Lunch on Your Own
1:30 – 3:00 p.m.Concurrent Session 4
Obesity, Diabetes & Metabolic Syndrome
BCardiac Hypertrophy and Dysfunction
CPregnancy and Preeclampsia I
1:30 – 3:00 p.m.Concurrent Session 4
Clinical Practice Clinical Science Track – Aldosterone and Primary Aldosteronism in Hypertension
The Potassium, Aldosterone, Blood Pressure Axis – David Ellison, MD, FAHA
The New Genetics of Aldosteronism  - Celso Gomez-Sanchez, MD, FAHA
Screening and Diagnosis of Aldosteronism 2018 - David A. Calhoun, MD, FAHA
Hyperaldosteronism as a Cause of Resistant Hypertension – Bryan Williams, MD, FAHA
3:00 – 3:30 p.m.Refreshment Break
3:30 – 5:30 p.m.Concurrent Session 5
– Inflammation, Immunity & Cytokines with 30-minute Mini Review Session
Recent Advances in our Understanding of Inflammation, Immunity & Cytokines – Ernesto L. Schiffrin, MD, PhD
B - Cerebrovascular Disease, Stroke, and Aging
– Renin Angiotensin System I with 30-minute Mini Review Session
Recent Advances in our Understanding of the Renin Angiotensin System – AH Jan Danser, PhD
3:30 – 5:30 p.m.Concurrent Session 5
D – Clinical Practice Clinical Science Track: Managing Hypertension in At-Risk-Populations

Goals of Hypertension Management in Patients with Chronic Kidney Disease – Sandra J. Taler, MD, FAHA
Strategies for Control of Hypertension in Renal Transplant Recipients – Michelle A. Josephson, MD
State-of-the-Art on Management of Pregnancy-Associated Hypertension – Mark Santillan, MD, PhD, FAHA
Managing Cardiovascular Complications in Patients Treated with VEGF Inhibitors and Other Chemotherapeutic Agents – AH Jan Danser, PhD
Treating Post Stroke Hypertension: Thresholds and Goals – José Biller, MD, FAAN, FACP, FAHA
Panel Discussion
5:30 – 7:00 p.m.POSTER SESSION I
Trainee Onsite Poster Competition with Reception

#Hypertension18 Friday, Sept. 7
7:00 – 8:00 a.m.Coffee and Exhibits
8:00 – 9:00 a.m.Session 6 - Recent Advances: Debate – Renal Denervation: Is There a Role in Essential Hypertension?
Pro: Ray Townsend, MD, FAHA
Con: George Bakris, MD, FAHA
9:00 – 10:00 a.m.Session 7 - Recent Advances: Hot Topics in Hypertension
Epigenetic Determinants of Cardiovascular Gene Expression: Vascular Endothelium – Phil Marsden, MD
Sex Differences in Mechanisms of Hypertension Association with Obesity – Eric Belin de Chantemele, MS, DSc, FAHA
10:00 – 10:30 a.m.Refreshment Break
10:30 – 11:15 a.m.Session 8 - Recent Advances: Hot Topics in Hypertension
The Progression from Hypertension to Congestive Heart Failure in Patients: How Do We Stop It? – Daniel Levy, MD, FAHA
SGLT Inhibitors for Hypertension, Renal and Cardiovascular Disease – Christopher Wilcox, MD, PhD, FAHA 
11:15 – 12:00 p.m.Session 9 - Recent Advances: Blood Pressure and Neurocognition
Will the New Guidelines Effect Cognition in Adults? – Jeff Williamson, MD
BP and Cognition in Children and Adolescents – Marc Lande, MD, MPH
12:00 – 1:30 p.m.Lunch on Your Own or
12:00 – 1:30 p.m.Expert Theater: Long-Term Results of Treatment Across a Broad Range of Patients with Type 2 Diabetes
Supported by Janssen Pharmaceuticals, Inc.
Lunch provided on a first come, first serve basis for the first 200 people
1:30 – 3:00 p.m.POSTER SESSION II
1:30 – 3:00 p.m.Session 10: Primary Care Track: The Evolving Landscape of Blood Pressure Guidelines, Part 1
Welcome and Introduction to Primary Care Track: Goals and Objectives – Jan Basile, MD, FAHA
What do the 2017 ACC/AHA Guidelines Actually Say? – Sandra Taler, MD, FAHA
Understanding the Data that Drove the 2017 ACC/AHA Guidelines – Paul Muntner, PhD, MHSc, FAHA
The Difference Between Blood Pressure Targets and Performance Measures: Brief Explanation of the Epidemiology of Achieved Blood Pressure – Brent Egan, MD
The American College of Physicians (ACP) and American Academy of Family Practice (AAFP) Perspective – Marie Brown, MD
3:00 – 3:30 p.m.Refreshment Break
3:30 – 4:00 p.m.Arthur C. Corcoran Memorial Lecture
Virend K. Somers, MD, PhD, FAHA
4:00 – 5:30 p.m.Concurrent Session 11
– Gender Differences and Sex Hormones
B – Hypertension Early Career Oral Awards Session
C – Renal Injury
3:30 – 5:30 p.m.Concurrent Session 11: D – Primary Care Track: The Evolving Landscape of Blood Pressure Guidelines Part 2: Areas of Controversy
Blood Pressure Goals in Diabetes and Chronic Kidney Disease – George Bakris, MD, FAHA
The Older Patient with Hypertension – Matthew Sorrentino, MD, FAHA
Treating Hypertension in Low-Risk Individuals: How Long Do We Hold Off on Pharmacologic Treatment? – Stephen Williams, MD, MS
Can't We All Just Get Along? Finding Consensus Among Guidelines and Statements – Michael Bloch, MD, FAHA
Case Based Discussion Panel on Areas of Controversy in the Guidelines
5:30 – 5:45 p.m.Refreshment Break
5:45 – 6:45 p.m.Session 12: Awards Session
Mid-Career Award for Research Excellence – Jennifer C. Sullivan, PhD, FAHA
The Harry Goldblatt Award for New Investigators – Amy C. Arnold, PhD, FAHA
British and Irish Hypertension Society Young Investigator Award – Luca Faconti, King's College London
High Blood Pressure Research Council of Australia Award – Ashenafi Aaileyesus Bertrie, University of Melbourne
Stephanie Watts Career Development Award Finalist Competition – Katrina Mirabito Colafella, PhD; Nirupama Ramkumar, MD, MPH; Jennifer L. Sones, DVM, PhD 
7:00 – 11:00 p.m.Trainee Advocacy Mixer

Hypertension18 Saturday Sept 8
6:30 – 7:30 a.m.Coffee and Exhibits
7:30 – 9:00 a.m.Concurrent Session 13
A – Vascular Biology
B – Renal Hemodynamics and Tubular Transport
C – Hypertension Journal Case Studies
9:00 – 9:30 a.m.Donald Seldin Award Lecture
Paul A. Welling, MD, FAHA
7:30 – 9:30 a.m.Concurrent Session 13:
D – Primary Care Track: Emerging Issues in Hypertension Management

How Do Environmental Factors Effect Blood Pressure? – Robert E Brook, MD, FAHA
Treatment of Hypertension in the Women Considering Conception – Mark Santillan, MD, PhD, FACOG, FAHA
Remote Monitoring and Patient Self-Management - Is it the Future of BP Management? – Debbie L Cohen, MD
Management of Hyper-and-Hypo-Kalemia in Treated Hypertensive Patients – Matthew Weir, MD
Surgical and Percutaneous Interventions in Management of Hypertension – Ray Townsend, MD,FAHA
9:30 – 10:00 a.m.Refreshment Break
10:00 – 10:30 a.m.Harriet Dustan Award Lecture
Barbara T. Alexander, PhD, FAHA
10:30 – 12:00 p.m.Concurrent Session 14
A – Blood Pressure Monitoring, Control and Adherence to Treatment
B – Clinical Trials, Antihypertensive Drugs and Pharmacology
C – Neurogenic Mechanisms I
10:00 – 12:00 p.m.Concurrent Session 14
D – Primary Care Track: The Evolving Landscape of Blood Pressure Guidelines Part 3: Special Situations
Determining Adequacy of BP Control: Using Appropriate Technique and Integrating In and Out of Office Measurements – Daichi Shimbo, MD
Management of Resistant Hypertension: Have We Learned Anything New? – David Calhoun, MD, FAHA
Implementation of Pediatric Guidelines for Hypertension Management – Joshua Samuels, MD, MPH, FAHA
Case 1: Presented by Michael Fitzgerald, MD
Case 2: Presented by William J Elliott, MD, PhD, FAHA
12:00 – 1:30 p.m.Satellite Symposium: Renal Denervation and Blood Pressure Control: A Clinical Trial Update
Sponsored by Cardiovascular Research Foundation. Supported through an educational grant from Medtronic and Recor Medical.
Lunch provided on a first come, first served basis for the first 200 people.
12:00 – 1:30 p.m.or Lunch on your own
1:30 – 3:00 p.m.POSTER SESSION III
1:30 – 3:00 p.m.Session 15
Clinical Practice Clinical Science Track: Taking Hypertension into the Community

Part One: The Barbershop
Cluster Randomized Trials of Blood Pressure Reductions in Black Barbershops – Ronald G. Victor, MD, FAHA; Ciantel A.Blyler, PharmD; Barber Video Presentation
Part Two: Telemonitoring, Self-Monitoring, and BP Control
The Role of Telemonitoring in Improving BP Control – Hayden Bosworth, PhD 
Telemonitoring vs. Self-Monitoring in BP Control: Does it Make a Difference? – Bryan Williams, MD, FRCP, FESC, FAHA
3:00 – 3:30 p.m.Refreshment Break
3:30 – 5:30 p.m.Concurrent Session 16
A – Salt and Hypertension
B – Aldosterone, Receptors and Other Hormones
C – Asian Pacific Symposium on Cardiovascular Research 
3:30 – 5:30 p.m.Concurrent Session 16
D – Clinical Practice Clinical Science Track: AHA Council on Hypertension/ESC Council on Hypertension Joint Session
ESC/ESH Guideline on Hypertension 2018 – Bryan Williams, MD, FRCP, FESC, FAHA
The Canadian Guideline: Differences and Similarities to the European Guideline – Ernesto Schiffrin, CM, MD, PhD, FRSC, FRCPC, FACP
US, European and Canadian Guidelines: What is the Clinician to Do? – Michael A. Weber, MD, FACP, FACC, FAHA
Device-Based Treatment for Hypertension: Who, When and How? – Felix Mahfoud, MD
5:45 – 6:30 p.m.Session 17
The Excellence in Hypertension Research Award
R. Clinton Webb, PhD, FAHA
Paul K. Whelton, MD, MSc, MBBCH, FAHA
7:00 – 7:30 p.m.Social Hour
Cash Bar – Dinner ticket required for entrance
7:30 – 10:30 p.m.Annual Hypertension Scientific Sessions Award BanquetDinner ticket required
Join us in celebrating and recognizing all of our Awardees, including the recipients of the Excellence in Hypertension Research Award.

Hypertension18 Sunday, Sept 9
6:30 – 7:30 a.m.Coffee and Exhibits
7:30 – 9:00 a.m.Concurrent Session 18
– Neurogenic Mechanisms II
B – Vascular Stiffness
C – Epidemiology, Genetics and Epigenetics
9:00 – 9:30 a.m.The Lewis K. Dahl Memorial Lecture
Dominik N. Müller, PhD
8:00 – 9:20 a.m.Concurrent Session 18
D – Clinical Practice Clinical Science Track: Getting It Done: Practical Ways to Improve Blood Pressure Control, Part 1
Introduction – William J. Elliott, MD, PhD, FAHA; Keith Ferdinand, MD, FAHA
Secrets to Sustain a Low-Sodium DASH Diet In Your Patient – Crystal Tyson, MD
How to Get Your Patients to Exercise – Ross Arena, PhD, PT, FAHA
Practical Pearls in Using Weight-loss Medications in Patients with Hypertension – Robert F. Kushner, MD
How to Determine and Incorporate CVD Risk to Guide Intensity of Blood Pressure Management – Robert A. Phillips, MD, PhD, FAHA
9:30 – 10:00 a.m.Refreshment Break (for Concurrent Session 18 A-B-C)
9:20 – 9:40 a.m.Refreshment Break (for Concurrent Session 18 D)
10:00 – 11:30 a.m.Concurrent Session 19
A – Oxidative Stress, Nitric Oxide, Endothelin, and Other Endothelial Factors
B – Inflammation, Immunity and Cytokines II
C – Pregnancy and Preeclampsia II
9:40 – 11:00 a.m.Concurrent Session 19
D – Clinical Practice Clinical Science Track: Getting It Done: Practical Ways to Improve Blood Pressure Control, Part 2
Getting Ambulatory Blood Pressure Monitoring Reimbursed – Steve Yarows, MD, FAHA
Which Device Should We Use for Office BP Measurement – Martin G. Myers, MD
Promoting Accurate Home Blood Pressure Monitoring – Daichi Shimbo, MD
Team-based Approach to Blood Pressure Telemonitoring – Karen Margolis, MD, MPH
11:00 a.m. / 11:30 a.m.Meeting Adjourns (11:00 a.m. for Concurrent Session 19 D)
Meeting Adjourns (11:30 a.m. for Concurrent Session 19 A-B-C)

About This Meeting

AHA’s Hypertension 2018 Scientific Sessions, focusing on recent advances in basic and clinical research on hypertension, is considered the premier scientific meeting on the subject in the world. A collaborative effort between the Council on Hypertension and the Council on the Kidney in Cardiovascular Disease, the science submitted to this conference continues to bring us the most up to date developments on our understanding of: the causes of hypertension; its relationship to stroke, cardiac disease and kidney dysfunction; and the most effective means for detecting, evaluating and treating high blood pressure across diverse populations.

The planned agenda includes 18 sessions during 3½ days, with more than 500 presentations focused on recent advances in hypertension research including oral and poster presentations selected from abstracts submitted by clinical and basic researchers as well as the Primary Care and Clinical Practice Clinical Science Tracks for Clinicians.

Target Audience

The conference is designed to benefit research scientists, clinicians, and other healthcare professionals in the fields of hypertension research, cardiology, nephrology, endocrinology and related disciplines.

Learning Objectives

  1. Discuss changes to the AHA/ACC guidelines for the management of hypertension and their clinical implications.
  2. Describe opportunities to improve blood pressure measurement in the clinical setting to provide more accurate results.
  3. Identify immune and inflammatory mechanisms that contribute to the development of hypertension and hypertension-related end-organ damage and discuss the research and clinical implications.
  4. Educate participants about medical approaches for the management of comorbid obesity in patients with hypertension.
  5. Describe new and emerging strategies for treating resistant hypertension.
  6. Describe participants on the impact of value-based reimbursement on hypertension management and identify opportunities to improve its management.